Oben

Eckert & Ziegler startet Produktion von Actinium-225 und ebnet den Weg für die Versorgung mit GMP-Material

2. Dezember 2024 | Berlin

Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today celebrates the successful start of Actinium-225 (Ac-225) production, addressing the global shortage of this critical radionuclide. This milestone marks a major success of the common project with the Nuclear Physics Institute of the Czech Academy of Sciences (ÚJF). The test production demonstrated that the choice of technology was appropriate to achieve the expected parameters of the product.

In parallel with production, Eckert & Ziegler has commenced the validation process to produce GMP-grade Ac-225, crucial for clinical and commercial use. It is expected to become available in the first half of 2025, unlocking new opportunities for pharmaceutical companies developing alpha-emitting radiopharmaceuticals.

The production facility employs innovative cyclotron-based methods to generate Ac-225 from Radium-226, marking a pivotal advancement in isotope production. “This milestone underscores our commitment to advancing cancer treatment through the reliable supply of radioisotopes,” said Dr. Lutz Helmke, Managing Director of Eckert & Ziegler Radiopharma GmbH. “The commencement of Ac-225 production not only addresses the current shortage but also fortifies Eckert & Ziegler’s position as a key player in the future of radioligand therapy.”

The successful start of Ac-225 production is a direct result of the close collaboration between Eckert & Ziegler and the ÚJF. Drawing on decades of expertise in nuclear research and radiopharmaceutical development, ÚJF has played a crucial role in designing and optimizing this production pathway for Ac-225. Incorporating custom-engineered solutions by Isotope Technologies Dresden GmbH, Eckert & Ziegler’s hot cell division, the production process is designed to be efficient and sustainable.

The start of production positions Eckert & Ziegler at the forefront of the radiopharmaceutical industry’s transformation, offering a reliable and scalable source of Ac-225 for clinical development and commercial manufacturing.

Kontaktieren Sie uns

Eckert & Ziegler Medical
+49 30 94 10 84 0
+49 30 94 10 84 470
Der Medical-Newsletter Abonnieren und auf dem Laufenden bleiben

Möchten Sie die neuesten Informationen zu unseren Produkten und aktuellen Entwicklungen erhalten? Möchten Sie über anstehende Veranstaltungen informiert werden? Unser Newsletter wird regelmäßig verschickt und Sie können ihn jederzeit wieder abbestellen.

Bitte wählen Sie mindestens einen Themenbereich.

ABONNIEREN SIE UNSEREN NEWSLETTER

WordPress Cookie Plugin von Real Cookie Banner